Screener / SEC EDGAR /CIK 0001384101 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

Veracyte, Inc. VCYT

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 26, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Net income

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+174.9%

“Other income, net, increased $0.8 million for the year ended December 31, 2025 compared to 2024, primarily due to an increase of $6.0 million due to foreign currency revaluation and an increase of $1.6 million of interest and dividend income, partially offset by a loss of $6.7 million due to the deconsolidation of Veracyte SAS.”

Read it in the 10-K

Cash from operations

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+81.5%

The MD&A has no sentence that names a cause for this change.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

3.6% to 11.2% (+7.6 pts)

“Research and development expenses primarily include compensation expense, direct research and development expenses such as laboratory supplies and costs associated with setting up and conducting clinical studies at domestic and international sites, professional fees, depreciation and amortization, other miscellaneous expenses and allocation of facility and information technology expenses.”

Read it in the 10-K

Gross margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

66.9% to 70.1% (+3.2 pts)

The MD&A has no sentence that names a cause for this change.

Revenue

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+16.0%

“Testing revenue increased by $74.2 million, or 18%, driven by a $66.7 million increase in Decipher revenue and a $13.7 million increase in Afirma revenue.”

Read it in the 10-K

“Product revenue increased $0.7 million, or 5%, for the year ended December 31, 2025 compared to 2024, driven primarily by improved average selling price per test.”

Read it in the 10-K

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +16.0%

    “Testing revenue increased by $74.2 million, or 18%, driven by a $66.7 million increase in Decipher revenue and a $13.7 million increase in Afirma revenue.”

    Read it in the FY 2025 10-K

    “Product revenue increased $0.7 million, or 5%, for the year ended December 31, 2025 compared to 2024, driven primarily by improved average selling price per test.”

    Read it in the FY 2025 10-K
  • FY 2024 +23.5%

    “Testing revenue increased by $92.4 million, or 28%, driven by a $73.4 million increase in Decipher revenue and a $19.8 million increase in Afirma revenue.”

    Read it in the FY 2024 10-K

    “Product revenue decreased $1.9 million for the year ended December 31, 2024 compared to 2023, driven primarily by lower demand for product test kits, largely as a result of supplier quality and supply chain issues.”

    Read it in the FY 2024 10-K

Gross margin

0 of 2 years explained
  • FY 2025 +3.2 pts

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +3.3 pts

    The FY 2024 MD&A has no sentence that names a cause for this change.

Operating margin

1 of 2 years explained
  • FY 2025 +7.6 pts

    “Research and development expenses primarily include compensation expense, direct research and development expenses such as laboratory supplies and costs associated with setting up and conducting clinical studies at domestic and international sites, professional fees, depreciation and amortization, other miscellaneous expenses and allocation of facility and information technology expenses.”

    Read it in the FY 2025 10-K
  • FY 2024 +27.4 pts

    The FY 2024 MD&A has no sentence that names a cause for this change.

Cash from operations

0 of 2 years explained
  • FY 2025 +81.5%

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +69.8%

    The FY 2024 MD&A has no sentence that names a cause for this change.

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VCYT/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.